Key positives include a strong liquidity position for now, a relatively clean and liquid balance sheet, moderate leverage, and a clearly focused R&D strategy around immune modulation. The company has deep expertise in polymer chemistry and immunology, with differentiated lead programs that address significant unmet needs in autoimmune disease and oncology. Its asset-light model and history of technology collaboration also support potential partnerships with larger pharmaceutical players.

Major risks center on sustained heavy losses, significant negative cash flow, and continued dependence on capital markets or partners to fund operations. Clinical and regulatory risk is high: setbacks for rezpeg or NKTR‑255 could materially impair the company’s prospects. Competitive intensity in immunology and oncology is fierce, with many better-capitalized rivals working on overlapping mechanisms. Persistent cash burn also raises the prospect of future dilution or less favorable financing terms if investor sentiment turns against high-risk biotech names.

Looking ahead, Nektar’s trajectory is likely to be driven far more by scientific and clinical milestones than by near-term financial performance. The current financial profile is challenging and unsustainable on a stand-alone basis over the long term, but the company still has time and liquidity to advance its key programs. If rezpeg and NKTR‑255 deliver strong, reproducible data and progress through late-stage development, Nektar’s strategic position could improve markedly; if not, the combination of cash burn and competition may become increasingly difficult to manage. Overall, the story is high risk and highly contingent on the success and timing of its innovation pipeline.